B cell somatic hypermutation following COVID-19 vaccination with Ad26.COV2.S
Summary: The viral vector-based COVID-19 vaccine Ad26.COV2.S has been recommended by the WHO since 2021 and has been administered to over 200 million people. Prior studies have shown that Ad26.COV2.S induces durable neutralizing antibodies (NAbs) that increase in coverage of variants over time, even...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-05-01
|
| Series: | iScience |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589004224009386 |
| _version_ | 1797200785924161536 |
|---|---|
| author | Catherine Jacob-Dolan Michelle Lifton Olivia C. Powers Jessica Miller Nicole P. Hachmann Mya Vu Nehalee Surve Camille R. Mazurek Jana L. Fisher Stefanie Rodrigues Robert C. Patio Trisha Anand Mathieu Le Gars Jerald Sadoff Aaron G. Schmidt Dan H. Barouch |
| author_facet | Catherine Jacob-Dolan Michelle Lifton Olivia C. Powers Jessica Miller Nicole P. Hachmann Mya Vu Nehalee Surve Camille R. Mazurek Jana L. Fisher Stefanie Rodrigues Robert C. Patio Trisha Anand Mathieu Le Gars Jerald Sadoff Aaron G. Schmidt Dan H. Barouch |
| author_sort | Catherine Jacob-Dolan |
| collection | DOAJ |
| description | Summary: The viral vector-based COVID-19 vaccine Ad26.COV2.S has been recommended by the WHO since 2021 and has been administered to over 200 million people. Prior studies have shown that Ad26.COV2.S induces durable neutralizing antibodies (NAbs) that increase in coverage of variants over time, even in the absence of boosting or infection. Here, we studied humoral responses following Ad26.COV2.S vaccination in individuals enrolled in the initial Phase 1/2a trial of Ad26.COV2.S in 2020. Through 8 months post vaccination, serum NAb responses increased to variants, including B.1.351 (Beta) and B.1.617.2 (Delta), without additional boosting or infection. The level of somatic hypermutation, measured by nucleotide changes in the VDJ region of the heavy and light antibody chains, increased in Spike-specific B cells. Highly mutated mAbs from these sequences neutralized more SARS-CoV-2 variants than less mutated comparators. These findings suggest that the increase in NAb breadth over time following Ad26.COV2.S vaccination is mediated by affinity maturation. |
| first_indexed | 2024-04-24T07:37:10Z |
| format | Article |
| id | doaj.art-319b65fba338482abc0eb9e090cc8de1 |
| institution | Directory Open Access Journal |
| issn | 2589-0042 |
| language | English |
| last_indexed | 2024-04-24T07:37:10Z |
| publishDate | 2024-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | iScience |
| spelling | doaj.art-319b65fba338482abc0eb9e090cc8de12024-04-20T04:17:45ZengElsevieriScience2589-00422024-05-01275109716B cell somatic hypermutation following COVID-19 vaccination with Ad26.COV2.SCatherine Jacob-Dolan0Michelle Lifton1Olivia C. Powers2Jessica Miller3Nicole P. Hachmann4Mya Vu5Nehalee Surve6Camille R. Mazurek7Jana L. Fisher8Stefanie Rodrigues9Robert C. Patio10Trisha Anand11Mathieu Le Gars12Jerald Sadoff13Aaron G. Schmidt14Dan H. Barouch15Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA; Ragon Institute of Mass General, MIT, and Harvard, Cambridge, MA, USA; Harvard Medical School, Department of Microbiology, Boston, MA, USA; Harvard Medical School, Department of Immunology, Boston, MA, USACenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USACenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USACenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USACenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USARagon Institute of Mass General, MIT, and Harvard, Cambridge, MA, USACenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USACenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USACenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USACenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USACenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USACenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USAJanssen Vaccines and Prevention B.V., Leiden, the NetherlandsJanssen Vaccines and Prevention B.V., Leiden, the NetherlandsRagon Institute of Mass General, MIT, and Harvard, Cambridge, MA, USA; Harvard Medical School, Department of Microbiology, Boston, MA, USACenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA; Ragon Institute of Mass General, MIT, and Harvard, Cambridge, MA, USA; Harvard Medical School, Department of Immunology, Boston, MA, USA; Corresponding authorSummary: The viral vector-based COVID-19 vaccine Ad26.COV2.S has been recommended by the WHO since 2021 and has been administered to over 200 million people. Prior studies have shown that Ad26.COV2.S induces durable neutralizing antibodies (NAbs) that increase in coverage of variants over time, even in the absence of boosting or infection. Here, we studied humoral responses following Ad26.COV2.S vaccination in individuals enrolled in the initial Phase 1/2a trial of Ad26.COV2.S in 2020. Through 8 months post vaccination, serum NAb responses increased to variants, including B.1.351 (Beta) and B.1.617.2 (Delta), without additional boosting or infection. The level of somatic hypermutation, measured by nucleotide changes in the VDJ region of the heavy and light antibody chains, increased in Spike-specific B cells. Highly mutated mAbs from these sequences neutralized more SARS-CoV-2 variants than less mutated comparators. These findings suggest that the increase in NAb breadth over time following Ad26.COV2.S vaccination is mediated by affinity maturation.http://www.sciencedirect.com/science/article/pii/S2589004224009386Health sciencesImmunityImmune responseVirology |
| spellingShingle | Catherine Jacob-Dolan Michelle Lifton Olivia C. Powers Jessica Miller Nicole P. Hachmann Mya Vu Nehalee Surve Camille R. Mazurek Jana L. Fisher Stefanie Rodrigues Robert C. Patio Trisha Anand Mathieu Le Gars Jerald Sadoff Aaron G. Schmidt Dan H. Barouch B cell somatic hypermutation following COVID-19 vaccination with Ad26.COV2.S iScience Health sciences Immunity Immune response Virology |
| title | B cell somatic hypermutation following COVID-19 vaccination with Ad26.COV2.S |
| title_full | B cell somatic hypermutation following COVID-19 vaccination with Ad26.COV2.S |
| title_fullStr | B cell somatic hypermutation following COVID-19 vaccination with Ad26.COV2.S |
| title_full_unstemmed | B cell somatic hypermutation following COVID-19 vaccination with Ad26.COV2.S |
| title_short | B cell somatic hypermutation following COVID-19 vaccination with Ad26.COV2.S |
| title_sort | b cell somatic hypermutation following covid 19 vaccination with ad26 cov2 s |
| topic | Health sciences Immunity Immune response Virology |
| url | http://www.sciencedirect.com/science/article/pii/S2589004224009386 |
| work_keys_str_mv | AT catherinejacobdolan bcellsomatichypermutationfollowingcovid19vaccinationwithad26cov2s AT michellelifton bcellsomatichypermutationfollowingcovid19vaccinationwithad26cov2s AT oliviacpowers bcellsomatichypermutationfollowingcovid19vaccinationwithad26cov2s AT jessicamiller bcellsomatichypermutationfollowingcovid19vaccinationwithad26cov2s AT nicolephachmann bcellsomatichypermutationfollowingcovid19vaccinationwithad26cov2s AT myavu bcellsomatichypermutationfollowingcovid19vaccinationwithad26cov2s AT nehaleesurve bcellsomatichypermutationfollowingcovid19vaccinationwithad26cov2s AT camillermazurek bcellsomatichypermutationfollowingcovid19vaccinationwithad26cov2s AT janalfisher bcellsomatichypermutationfollowingcovid19vaccinationwithad26cov2s AT stefanierodrigues bcellsomatichypermutationfollowingcovid19vaccinationwithad26cov2s AT robertcpatio bcellsomatichypermutationfollowingcovid19vaccinationwithad26cov2s AT trishaanand bcellsomatichypermutationfollowingcovid19vaccinationwithad26cov2s AT mathieulegars bcellsomatichypermutationfollowingcovid19vaccinationwithad26cov2s AT jeraldsadoff bcellsomatichypermutationfollowingcovid19vaccinationwithad26cov2s AT aarongschmidt bcellsomatichypermutationfollowingcovid19vaccinationwithad26cov2s AT danhbarouch bcellsomatichypermutationfollowingcovid19vaccinationwithad26cov2s |